GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gujarat Terce Laboratories Ltd (BOM:524314) » Definitions » Cyclically Adjusted Revenue per Share

Gujarat Terce Laboratories (BOM:524314) Cyclically Adjusted Revenue per Share : ₹56.81 (As of Dec. 2023)


View and export this data going back to 1994. Start your Free Trial

What is Gujarat Terce Laboratories Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Gujarat Terce Laboratories's adjusted revenue per share for the three months ended in Dec. 2023 was ₹17.612. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹56.81 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Gujarat Terce Laboratories's average Cyclically Adjusted Revenue Growth Rate was 7.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-05-24), Gujarat Terce Laboratories's current stock price is ₹55.95. Gujarat Terce Laboratories's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was ₹56.81. Gujarat Terce Laboratories's Cyclically Adjusted PS Ratio of today is 0.98.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Gujarat Terce Laboratories was 1.19. The lowest was 0.09. And the median was 0.36.


Gujarat Terce Laboratories Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Gujarat Terce Laboratories's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gujarat Terce Laboratories Cyclically Adjusted Revenue per Share Chart

Gujarat Terce Laboratories Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 73.56 63.71 53.86

Gujarat Terce Laboratories Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 53.04 53.86 55.51 56.07 56.81

Competitive Comparison of Gujarat Terce Laboratories's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Gujarat Terce Laboratories's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gujarat Terce Laboratories's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gujarat Terce Laboratories's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Gujarat Terce Laboratories's Cyclically Adjusted PS Ratio falls into.



Gujarat Terce Laboratories Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Gujarat Terce Laboratories's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=17.612/152.9243*152.9243
=17.612

Current CPI (Dec. 2023) = 152.9243.

Gujarat Terce Laboratories Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 13.599 91.425 22.747
201406 7.835 94.103 12.733
201409 9.417 96.780 14.880
201412 8.336 96.780 13.172
201503 11.521 97.163 18.133
201506 7.354 99.841 11.264
201509 8.094 101.753 12.164
201512 9.098 102.901 13.521
201603 9.138 102.518 13.631
201606 6.930 105.961 10.001
201609 11.580 105.961 16.712
201612 8.234 105.196 11.970
201703 7.270 105.196 10.568
201706 5.975 107.109 8.531
201709 11.002 109.021 15.433
201712 10.364 109.404 14.487
201803 11.680 109.786 16.269
201806 9.083 111.317 12.478
201809 10.733 115.142 14.255
201812 11.261 115.142 14.956
201903 9.746 118.202 12.609
201906 9.349 120.880 11.827
201909 15.024 123.175 18.653
201912 13.720 126.235 16.621
202003 12.592 124.705 15.441
202006 6.712 127.000 8.082
202009 9.701 130.118 11.401
202012 9.471 130.889 11.065
202103 7.863 131.771 9.125
202106 13.412 134.084 15.297
202109 13.621 135.847 15.333
202112 14.414 138.161 15.954
202203 12.579 138.822 13.857
202206 12.697 142.347 13.640
202209 16.867 144.661 17.830
202212 16.044 145.763 16.832
202303 17.298 146.865 18.012
202306 14.426 150.280 14.680
202309 16.174 151.492 16.327
202312 17.612 152.924 17.612

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Gujarat Terce Laboratories  (BOM:524314) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Gujarat Terce Laboratories's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=55.95/56.81
=0.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Gujarat Terce Laboratories was 1.19. The lowest was 0.09. And the median was 0.36.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Gujarat Terce Laboratories Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Gujarat Terce Laboratories's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Gujarat Terce Laboratories (BOM:524314) Business Description

Traded in Other Exchanges
N/A
Address
Near Shivalik High-Street,, D/801 & 802,The First,, Behind Keshavbaug Party Plot,, Vastrapur,, Ahmedabad, GJ, IND, 380015
Gujarat Terce Laboratories Ltd is an India company having business in the medical and pharmaceutical preparations. It is engaged in the manufacturing of tablets, capsules, and syrup and injection. It offers branded as well as generic formulations covering different therapeutic areas such as antibiotics, respiratory, nutraceuticals, gastrointestinal, anti-fungal, and many more. Some of the main brands are Acolate, Tynol, DFS, Resplash , Aziter and others.

Gujarat Terce Laboratories (BOM:524314) Headlines

No Headlines